Nordea Investment Management AB Raises Stock Position in AbbVie Inc. $ABBV

Nordea Investment Management AB grew its holdings in AbbVie Inc. (NYSE:ABBV) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,495,558 shares of the company’s stock after purchasing an additional 6,081 shares during the quarter. AbbVie accounts for about 0.9% of Nordea Investment Management AB’s holdings, making the stock its 18th biggest holding. Nordea Investment Management AB owned about 0.25% of AbbVie worth $1,013,119,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of AbbVie by 15.7% during the first quarter. Jones Financial Companies Lllp now owns 178,952 shares of the company’s stock worth $36,790,000 after purchasing an additional 24,307 shares in the last quarter. First Hawaiian Bank raised its stake in AbbVie by 0.8% in the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after buying an additional 60 shares in the last quarter. Finally, RDA Financial Network lifted its holdings in AbbVie by 28.6% during the 2nd quarter. RDA Financial Network now owns 2,594 shares of the company’s stock worth $482,000 after buying an additional 577 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of AbbVie stock opened at $219.99 on Tuesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market capitalization of $388.80 billion, a P/E ratio of 166.66, a PEG ratio of 0.92 and a beta of 0.36. The company’s fifty day moving average is $226.75 and its two-hundred day moving average is $215.76.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a voluntary agreement with the Trump administration that includes a pledge to invest $100 billion in U.S. R&D and capital over the next decade and an exemption from tariffs and future pricing mandates — a regulatory win that reduces trade/tariff uncertainty and signals long‑term U.S. investment. AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
• Positive Sentiment: AbbVie is buying a Tempe, Arizona manufacturing facility from West Pharmaceutical Services and acquiring manufacturing/supply rights for the SmartDose 3.5mL on‑body delivery system — immediate capacity and device IP that support next‑generation injectable medicines and reduce supply risks. AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
• Positive Sentiment: AbbVie inked an exclusive licensing/development deal with RemeGen for RC148, a PD‑1/VEGF bispecific antibody, in a pact worth up to roughly $4.95–$5.6 billion in milestones — a meaningful oncology pipeline add that could drive long‑term upside if clinical development succeeds. AbbVie, RemeGen partner on experimental solid tumor treatment
• Neutral Sentiment: AbbVie joined other large drugmakers calling for the FDA to modernize post‑approval change rules — could improve manufacturing flexibility long‑term but timing and regulatory outcomes are uncertain. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: AbbVie reported completion of its ABBV‑932 bipolar depression Phase 2 trial — a development milestone investors will watch for data readouts, but clinical timing/outcomes remain the next catalysts. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion: What Investors Should Watch Next
• Negative Sentiment: As part of the U.S. agreement, AbbVie agreed to provide lower Medicaid prices (via TrumpRx) for a three‑year period — this pricing concession introduces near‑term revenue/margin risk and is the main downside investors are weighing against the tariff relief and investment commitments. Abbvie, US reach agreement to cut drug prices

Analysts Set New Price Targets

A number of research firms have recently commented on ABBV. Morgan Stanley increased their price objective on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Raymond James Financial set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. Finally, Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.